CYCLAFEM 1/35

Post-LOE

ethinyl estradiol; norethindrone

Pfizer

ANDAORAL-28TABLET

Approved

Nov 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CYCLAFEM 1/35 (ethinyl estradiol; norethindrone) by Pfizer is clinical pharmacology combined oral contraceptives combined oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 2010.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Combined Oral Contraceptives Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into…

Indications (1)

pregnancy in women

Company

Worked on CYCLAFEM 1/35 at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.